TORONTO, October 5, 2018 – Alternate Health Corp (“Alternate Health” or the “Company”) (CSE:AHG) (OTC:AHGIF), an international corporation that provides software solutions for the medical cannabis industry, today announced that the Company has entered into a software-as-a-service agreement with Liberty Health Sciences (“Liberty”), a premiere producer and dispenser of medical cannabis in the U.S., to provide e-commerce and digital transaction services in the Florida market.
“FlorPass has received tremendous response from our physician partners in Florida and we are pleased to be working with Liberty to bring new and innovative solutions to our rapidly expanding patient population,” says Dr. Michael Murphy, Chairman and CEO of Alternate Health. “Our team has developed a truly unique system and, through the agreement with Liberty, we are positioned for excellent growth in the Florida market.”
Liberty Health Sciences and Alternate Health were granted approval by the Florida Department of Health to implement FlorPass as the state’s first online shopping portal for medical cannabis equipped with a digital transaction system. Patients will now have the ability to browse medical cannabis products, make purchases and arrange delivery through the FlorPass secure online portal. FlorPass is the patient management software of choice for many of the state’s leading cannabis clinics and physicians, representing nearly 6,000 medical cannabis patients.
“We are proud to partner with a market leader and innovator like Alternate Health to provide best in class ecommerce access to the quality, value, and industry-leading expertise of our Liberty brands and services,” said George Scorsis, CEO of Liberty Health Sciences. “Our customers will now have online access to our growing product line with easy to navigate search capabilities, including filtering by brand and price. FlorPass is the perfect solution for us to deliver on our promise of exceptional user experience without sacrificing functionality or security.”
FlorPass charges a transaction fee based on a percentage of sales through the system’s e-commerce platform. Alternate Health anticipates strong revenues based on the growing patient base and Liberty’s strong brand presence across the state.
FlorPass is a blockchain-enabled software platform that manages the end-to-end transactions involved in providing safe access to medical cannabis to eligible patients. The system is accessible by the patient, certified doctors and licensed dispensaries, linked through a seamless interface, and is used to facilitate online purchases of medical cannabis and provide enhanced medical treatment recommendations, with a focus on improving patient outcomes.
About Liberty Health Sciences Inc.
Liberty is the cannabis provider committed to providing a trusted, high quality cannabis experience because of our genuine care for all cannabis users and a focus on operational excellence from seed to sale and beyond. Liberty’s stringent investment criteria for expansion maximizes returns to shareholders, while focusing on significant near-and mid-term opportunities while keeping consumers’ well-being at the forefront of what we do. Liberty has an extensive background in highly regulated industries and leverages its commercial greenhouse expertise to drive low-cost production. For more information, please visit: www.libertyhealthsciences.com.
FlorPass is the U.S. equivalent of Alternate Health’s cornerstone CanaPass Cannabis Compliance technology. Alternate Health’s CanaPass system is currently live nationwide in Canada through a partnership with National Access Cannabis (‘NAC’), Canada’s largest chain of medical cannabis clinics. Alternate Health’s agreement with Liberty to use FlorPass is based on a fee calculated as a percent of total transactions made in the system and has been established for an initial period of 6 months with an automatic renewal period of 1 year unless either party opts to terminate.
About Alternate Health
Alternate Health Corp. (CSE: AHG, OTCQB: AHGIF) Alternate Health has established multiple arms-length operations within the medical cannabis industry, each of which drives consumers, data and strategic opportunities to the company’s other verticals. This sophisticated cross-integration of the company’s enterprises has positioned Alternate Health as one of the only cannabis companies that delivers consistent revenue and intellectual property without growing, manufacturing or distributing the cannabis plant. Through its software solutions, data analytics, and patented delivery systems, Alternate Health’s goal is to be the global authority on scientific and clinical support for cannabis in regulated markets. Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders.
Alternate Health resides in the cannabis sector along with companies like GW Pharmaceuticals, AXIM Biotechnologies Inc., Canopy Growth Corporation, and Aphria Inc. Alternate Health is differentiated from other cannabis companies by its focus on ancillary services for patients, healthcare professionals and regulatory providers rather than selling a commodity. For more information about Alternate Health Corp., visit www.alternatehealth.ca.
Investor Relations Contact:
Jim Griffiths, Director
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as “forward-looking statements”. Forward-looking statements may be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company’s future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.